Back

Acoramidis significantly improves NT-proBNP indices that indicate ATTR-CM disease progression and predict subsequent mortality: insights from the ATTRibute-CM study

13 May 2024 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 3 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

7 More presentations in this session

Presentation thumbnail
Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study
Professor J. Youn (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Impact of the non-invasive diagnostic algorithm on clinical presentation and prognosis in a nationwide multicentric light-chain and transthyretin-related cardiac amyloidosis cohort
Doctor G. Tini Melato (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Validation of two clinical scores for transthyretin amyloid cardiomyopathy in a mediterranean cohort of patients at risk
Doctor M. Llevadot Sesmilo (Badalona, ES)
Abstract Slides Video
Presentation thumbnail
Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study
Doctor P. Van Der Meer (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Multimodality imaging to improve detection and prognostication of right ventricular involvement in cardiac sarcoidosis
Doctor J. Okafor (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 3

The Event

Event poster

Heart Failure 2024

13 May 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources